Xuchen Qi

Dr. Xuchen Qi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2024 in Pharmacological Research
Verified
Journal Article
Open access
SZShaojun Zhou
Shaojun Zhou
KCKaiwen Cheng
Kaiwen Cheng
YPYi Peng
Yi Peng
YLYuxi Liu
Yuxi Liu
QHQingqing Hu
Qingqing Hu
Lushan YuLushan Yu
Lushan Yu
The endoplasmic reticulum (ER) plays a pivotal role in protein folding and secretion, Ca2+ storage, and lipid synthesis in eukaryotic cells. When the burden of protein synthesis and folding required to be handled exceeds the processing capacity of the ER, the accumulation of misfolded/unfolded proteins triggers ER stress. In response to short-term ER stress, the unfolded protein response (UPR) is activated to allow cells to survive. When ER stress is severe and sustained, it typically provokes cell death through multiple approaches. It is well documented that ER stress and metabolic deregulation are functionally intertwined, both are considered contributing factors to the pathogenesis of liver diseases, including non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), ischemia/reperfusion (I/R) injury, viral hepatitis, liver fibrosis, and hepatocellular carcinoma (HCC). Hepatocytes are rich in smooth and rough ER, which harbor metabolic enzymes that are capable of sensing alterations in various nutritional status and external stimuli. Extensive research has focused on the molecular mechanism linking ER stress with metabolic enzymes. The purpose of this review is to summarize the current knowledge regarding the effects of ER stress on metabolic enzymes in various liver diseases and to provide potential therapeutic strategies for chronic liver diseases via targeting UPR.

4 July 2023 in PeerJ
Verified
Journal Article
Open access
PDF file
YWYongyan Wu
Yongyan Wu
YQYufeng Qian
Yufeng Qian
WPWei Peng
Wei Peng
XQXuchen Qi
Xuchen Qi
Glioma is the most common tumor of the central nervous system (CNS), with a 5-year survival rate of <35%. Drug therapy, such as chemotherapeutic and immunotherapeutic agents, remains one of the main treatment modalities for glioma, including temozolomide, doxorubicin, bortezomib, cabazitaxel, dihydroartemisinin, immune checkpoint inhibitors, as well as other approaches such as siRNA, ferroptosis induction, etc. However, the filter function of the blood-brain barrier (BBB) reduces the amount of drugs needed to effectively target CNS tumors, making it one of the main reasons for poor drug efficacies in glioma. Thus, finding a suitable drug delivery platform that can cross the BBB, increase drug aggregation and retainment in tumoral areas and avoid accumulation in non-targeted areas remains an unsolved challenge in glioma drug therapy. An ideal drug delivery system for glioma therapy should have the following features: (1) prolonged drug life in circulation and effective penetration through the BBB; (2) adequate accumulation within the tumor (3) controlled-drug release modulation; (4) good clearance from the body without significant toxicity and immunogenicity, etc. In this regard, due to their unique structural features, nanocarriers can effectively span the BBB and target glioma cells through surface functionalization, providing a new and effective strategy for drug delivery. In this article, we discuss the characteristics and pathways of different nanocarriers for crossing the BBB and targeting glioma by listing different materials for drug delivery platforms, including lipid materials, polymers, nanocrystals, inorganic nanomaterials, etc.

22 February 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
GLGang Li
Gang Li
HZHongyang Zhong
Hongyang Zhong
JWJie Wang
Jie Wang
YYYixin Yang
Yixin Yang
HLHuayun Li
Huayun Li
XQXuchen Qi
Xuchen Qi
Depression has become one of the most common mental illnesses, causing serious physical and mental harm. However, there remain unclear and uniform physiological indicators to support the diagnosis of clinical depression. This study aimed to use machine learning techniques to investigate the abnormal multidimensional EEG features in patients with depression. Resting-state EEG signals were recorded from 41 patients with depression and 34 healthy controls. Multiple dimensional characteristics were extracted, including power spectral density (PSD), fuzzy entropy (FE), and phase lag index (PLI). These three different dimensional characteristics with statistical differences between two groups were ranked by three machine learning algorithms. Then, the ranked characteristics were placed into the classifiers according to the importance of features to obtain the optimal feature subset with the highest classification accuracy. The results showed that the optimal feature subset contained 86 features with the highest classification accuracy of 98.54% ± 0.21%. According to the statistics of the optimal feature subset, PLI had the largest number of features among the three categories, and the number of beta features was bigger than other rhythms. Moreover, compared to the healthy controls, the PLI values in the depression group increased in theta and beta rhythms, but decreased in alpha1 and alpha2 rhythms. The PSD of theta and beta rhythms were significantly greater in depression group than that in healthy controls, and the FE of beta rhythm showed the same trend. These findings indicate that the distribution of abnormal multidimensional features is potentially useful for the diagnosis of depression and understanding of neural mechanisms.

1 March 2020 in World Neurosurgery
Verified
Journal Article
Closed access
YXYonglin Xie
Yonglin Xie
QLQin Lu
Qin Lu
CLCameron Lenahan
Cameron Lenahan
SYShuxu Yang
Shuxu Yang
DZDaoyang Zhou
Daoyang Zhou
XQXuchen Qi
Xuchen Qi

4 September 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
XQXuchen Qi
Xuchen Qi
WXWanxiu Xu
Wanxiu Xu
GLGang Li
Gang Li
Generalized anxiety disorder (GAD) and depressive disorder (DD) are distinct mental disorders, which are characterized by complex and unique neuroelectrophysiological mechanisms in psychiatric neurosciences. The understanding of the brain functional differences between GAD and DD is crucial for the accurate diagnosis and clinical efficacy evaluation. The aim of this study was to reveal the differences in functional brain imaging between GAD and DD based on multidimensional electroencephalogram (EEG) characteristics. To this end, 10 min resting-state EEG signals were recorded from 38 GAD and 34 DD individuals. Multidimensional EEG features were subsequently extracted, which include power spectrum density (PSD), fuzzy entropy (FE), and phase lag index (PLI). Then, a direct statistical analysis (i.e., ANOVA) and three ensemble learning models (i.e., Random Forest (RF), Light Gradient Boosting Machine (LightGBM), eXtreme Gradient Boosting (XGBoost)) were used on these EEG features for the differential recognitions. Our results showed that DD has significantly higher PSD values in the alpha1 and beta band, and a higher FE in the beta band, in comparison with GAD, along with the aberrant functional connections in all four bands between GAD and DD. Moreover, machine learning analysis further revealed that the distinct features predominantly occurred in the beta band and functional connections. Here, we show that DD has higher power and more complex brain activity patterns in the beta band and reorganized brain functional network structures in all bands compared to GAD. In sum, these findings move towards the practical identification of brain functional differences between GAD and DD.

1 February 2020 in Medicine
Verified
Journal Article
Open access
YXYonglin Xie
Yonglin Xie
QLQin Lu
Qin Lu
CLCameron Lenahan
Cameron Lenahan
SYShuxu Yang
Shuxu Yang
DZDaoyang Zhou
Daoyang Zhou
XQXuchen Qi
Xuchen Qi
Background: Glioblastomas are malignant brain tumors associated with high mortality and poor prognosis. Evidence from preclinical studies suggests that statins have an antitumor role, but their effects on the survival of patients with glioblastoma remain controversial. This meta-analysis attempts to assess the association between statins and glioblastoma. Methods: We searched 4 databases (PubMed, Web of Science, Embase, and Cochrane Library) for articles that evaluate the effect of statins on the survival of patients with glioblastoma. Two reviewers were asked to assess the quality of the studies and extract the data regarding progression-free survival (PFS) and overall survival (OS). Result: A total of 5 studies met the inclusion criteria with 430 statin users and 2089 nonstatin users. All 5 studies were retrospectively analyzed. The pooled hazard ratio (HR) and 95% confidence intervals (CIs) were calculated. There was no benefit of statins found pertaining to the survival of glioblastoma patients in both PFS (HR, 0.97; CI, 0.84–1.13) and OS (HR, 0.98; CI, 0.87–1.11). In a subgroup defined by the patterns of statin use, it was determined that usage before glioblastoma diagnosis favored the OS of patients (HR, 0.85). The result, however, failed to demonstrate a statistically significant difference. Conclusion: Use of statins was not associated with prolonged survival of patients with glioblastoma. Further well-designed randomized controlled trials are needed to confirm.